CLDX: Celldex Therapeutics, Inc Company Profile & Statistics

Celldex Therapeutics, Inc Profile

About

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Info & Links

CEO

Anthony S. Marucci

Headquarters

53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ 08827, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

136

Employees

186

Celldex Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization²

1.78B

Enterprise Value

1.74B

Enterprise Value/EBITDA(ttm)

-6.68

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

306.14

Price to Book(mrq)

2.96

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

75.00%

Operating Margin(ttm)

-3446.88%

Profit Margin(ttm)

-4875.42%

Return on Equity(ttm)

-33.22%

Return on Invested Capital(ttm)

-33.80%

Return on Assets(ttm)

-31.26%

Income Statement

Revenue(ttm)

2.60M

Revenue Per Share(ttm)

0.04

Gross Profit(ttm)

2.60M

EBITDA(ttm)³

-261.19M

Net Income Available to Common(ttm)

-224.53M

Diluted EPS(ttm)

-3.38

Share Statistics

Beta (5Y Monthly)

1.13

52-Week Change

1.91%

S&P 500 52-Week Change

15.47%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

66.45M

Dividend Yield

0.00%

Float⁴

63.52M

% Held by Insiders

4.40%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

583.22M

Total Cash Per Share(mrq)

8.78

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.01%

Quick Ratio(mrq)

13.01%

Book Value Per Share(mrq)

9.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.21

Free Cash Flow(ytd)

-148.44M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CLDX

Celldex Therapeutics, Inc